'Reverse vaccine' for diabetes passes test
LOS ANGELES — A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential strategy for treating those in the early stages of the disease, experts said.
The therapy is designed to protect cells in the pancreas that make insulin, a hormone the body needs to convert sugars and starches into energy. In people with Type 1 diabetes, the immune system goes haywire and attacks those crucial insulin-producing cells for reasons that medical researchers don't understand.
Researchers dubbed the treatment a reverse vaccine because it suppresses the immune system, instead of stimulating it. As hoped, the experimental vaccine reduced the number of immune system “killer” cells that went on the attack.
“We're trying to turn off one specific immune response,” said Dr. Lawrence Steinman, an immunologist at Stanford University and senior author of the study published Wednesday in Science Translational Medicine.
About 1.25 million Americans have Type 1 diabetes.
Show commenting policy
TribLive commenting policy
- VA Phoenix social worker on leave for Halloween costume
- Company backs away from pledge to cut drug’s $750-per-pill price
- Peanut glut poses hefty bailout tab for taxpayers
- Barrier nears completion in Indiana marsh to keep Asian carp from Great Lakes
- Military Academy bans pillow fights; 30 hurt during last one
- U.S. troops suspended in airstrike on Afghan hospital
- ‘Crisis mode’ near at U.S.-Mexico line as nearly 5,000 children try to cross border in October
- Obama signs $607B Defense bill but blasts GOP limits for Gitmo
- Student dies in traditional Ohio State University lake jump
- N.H. prep grad to appeal sex assault verdict
- Video prompts calls for probe of Chicago police